Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $1.18 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.16, down -1.69%. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 3.79 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.54 and its Current Ratio is at 8.54. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.Piper Sandler initiated its Overweight rating on May 31, 2024, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when Yoshiyama Annie sold 9,601 shares for $1.41 per share. The transaction valued at 13,537 led to the insider holds 130,663 shares of the business.
Yoshiyama Annie bought 9,601 shares of ALLO for $13,537 on Apr 21 ’25. On Mar 14 ’25, another insider, Chang David D, who serves as the President and CEO of the company, sold 46,668 shares for $1.96 each. As a result, the insider received 91,469 and left with 5,276,569 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 12685.18 while its Price-to-Book (P/B) ratio in mrq is 0.58.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -27.87%, while the 200-Day Moving Average is calculated to be -47.21%.
Shares Statistics:
A total of 212.21M shares are outstanding, with a floating share count of 143.20M. Insiders hold about 34.52% of the company’s shares, while institutions hold 64.70% stake in the company.
